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Background: Adipocyte-derived factors and regulators likely contribute to the metabolic syndrome (MetS) in patients
with central obesity. This study was undertaken to assess the contribution of leptin, adiponectin, and acylation stimulating
protein (ASP-C3ades/ARG) to hemodynamic (blood pressure [BP]) and metabolic (insulin, glucose, lipids) features of MetS.
Methods: In this study, leptin, adiponectin, and C3ades/ARG were measured at baseline and in response to an infusion of
Intralipid® and heparin in 12 lean healthy controls and 12 patients with MetS.
Results: Baseline plasma leptin (27.6 ± 6.2 vs. 10.9 ± 3.8 ng/mL, p < 0.01) and plasma C3ades/ARG (273 ± 79 vs
198 ± 57 mg/dL, p < 0.05) were higher in the MetS than control group, whereas baseline plasma adiponectin
was higher in the control than MetS group (9.9 ± 1.9 vs. 5.4 ± 0.6 g/mL). Plasma leptin correlated with body
mass index (BMI), systolic and diastolic BP (r = 0.53-0.77, p < 0.01). Conversely, adiponectin correlated inversely
with insulin, glucose, waist circumference, and insulin sensitivity (r = 0.48-0.51, p ≤ 0.02). Plasma triglycerides
increased similarly in MetS and control groups after 4-hours of Intralipid and heparin. C3ades/ARG increased
only in lean volunteers. The decrease in triglycerides 1-hour post-infusion was lower in the MetS than control
group (-116 ± 33 vs. -282 ± 81 mg/dL, p = 0.01) and correlated inversely with the change in C3ades/ARG.
Conclusion: These data suggest that leptin is more closely associated with hemodynamic (BP) aspects of MetS,
whereas adiponectin and C3ades/ARG are more closely associated with metabolic components.
Keywords: Intralipid® and heparin, Adiponectin, Leptin, ASP/C3adesARG, Lean normotensives, Metabolic
syndrome subjectsBackground
A rapidly growing body of literature indicates that
adipocyte-derived signaling hormones and regulators
of adipocyte function play an important role in the patho-
genesis and complications of metabolic syndrome (MetS).
Leptin, an adipocyte secreted hormone, has multiple car-
diovascular functions and is associated with sympathetic
activation, angiogenesis, oxidative stress and thrombosis
[1-4]. Adiponectin, a novel adipocyte-derived collagen-like
protein, has been associated linked to anti-inflammatory* Correspondence: hipheno@gmail.com
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unless otherwise stated.and anti-atherogenic proprieties [5,6]. Leptin and adipo-
nectin were inversely related in normal controls and obese
women [7]. C3adesARG (ASP) is a complement C3a com-
ponent resulted from the removal of the carboxy-terminal
arginine. ASP/C3adesARG increases postprandially and
correlated with the rate of triglyceride clearance in one
study, but levels did not change post-prandially in another
report [8,9]. ASP/C3adesARG is an adipocyte product that
correlated with postprandial lipemia in subjects with cor-
onary artery disease [10]. These observations suggest that
different adipocyte-derived factors and the balance be-
tween these factors contribute to various features of MetS
and its cardiovascular diseases risk factors. At least some
of these factors are responsive to an acute oral and/or
parenteral lipid load. The aim of this study was to
evaluate the relationship of plasma leptin, adiponectin,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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response of these factors to acute hyperlipidemia. Subjects
for this study included obese subjects with features of




Twelve subjects with features of MetS (waist circumfer-
ence ≥88 cm for women and ≥102 cm for men, triglyc-
erides >150 mg/dL and/or HDL-cholesterol <45 for women
or <40 mg/dL for men, BP <130-159/85-99 mmHg) and 12
healthy volunteers (waist circumference <88 cm for women
and <102 cm for men, BP <130/85 mmHg) with normal
lipids matched for age, race, and gender were evaluated as
described previously [11]. In brief, subjects read and signed
a written informed consent document approved by the
Institutional Review Board of Medical University of South
Carolina. They were scheduled for 3 consecutive weekly
screening visits to ensure eligibility. Subjects were consid-
ered in MetS group when they met at least 3 criteria de-
fined by the Adult Treatment Panel III classification [12].
Physiological data
During the qualifying visits, subjects had their blood pres-
sure and heart rate measured in triplicate in the sitting
position. Blood pressures were measured by a trained ob-
server using a mercury sphygmomanometer and appropri-
ately sized cuff. The first Korotkoff sound defined systolic
blood pressure and the disappearance of 5th Korotkoff
sound determined diastolic blood pressure. Heart rate was
measured by palpation of the radial pulse for 30 seconds
between the 2nd and 3rd measurements of blood pressure
with subjects in the seated position.
Biochemical measurements
Blood for non-esterified fatty acids (NEFAs) was drawn
into prechilled Eppendorf tubes containing paraoxon [13].
Plasma was stored at -70°C before analyzing the total
plasma NEFAs using the 63Ni method [14].
Lipids and lipoproteins
Triglycerides were measured by fluorometric method.
Total cholesterol was measured by the colorimetric
method, and HDL- cholesterol was prepared from whole
plasma by precipitation with phosphotungstate-MgCl2
[15]. LDL-cholesterol and VLDL-cholesterol were calcu-
lated [16].
Adipocyte factors
Plasma leptin was measured by radioimmunoassay method
and plasma adiponectin was measured by the Elisa method.
Plasma ASP/C3adesARG was measured by the Elisa sand-
wich Immunoassay method. Total antioxidant capacity wasmeasured by the ferric reducing activity of plasma (FRAP)
assay under fasting conditions.
Total antioxidant capacity
FRAP assay was performed as previously described [17].
FRAP activity was measured in triplicate on each sample
and the mean of the three values was used in the
analysis.
Insulin and HOMAir
Plasma insulin was measured by radioimmunoassay method
and the homeostatic model assessment for insulin sensitivity
(HOMAir) was calculated dividing glucose (mmol/L) ×
insulin (IU/L) by 22.5.
Protocol
On the study day subjects were admitted to the outpatient
General Clinical Research Center (GCRC) at 08:00 follow-
ing an overnight fast. Intravenous access was established
in both arms, with one side for obtaining blood samples
and the other for infusion of Intralipid® and heparin.
After 30 minutes of resting blood samples were drawn
for serum lipids and plasma glucose, insulin, total anti-
oxidant capacity (FRAP assay), NEFAs, triglycerides,
adiponectin, and ASP/C3adesARG. An infusion was
then started of 20% Intralipid® (Baxter Healthcare Corp.,
Glendale, CA) at 0.8 ml/m2/min and heparin (200 U bolus,
followed by infusion at 1000 U/h). Heparin was given to
activate lipoprotein lipase and accelerate the hydrolysis of
fatty acids from triglycerides. Blood samples were obtained
for triglycerides, NEFAs, leptin, adiponectin, insulin, and
ASP/C3adesARG at 2-hours and 4-hours of the Intralipid®
and heparin infusion.
Statistical analysis
Group differences in dichotomous variables including gen-
der and race were examined using the Chi-square test.
Age, casual blood pressure and heart rate were shown as
median, minimum and maximum and body mass index
(BMI) in media and standard error. The Student’s unpaired
t-test was used to compare casual blood pressure, heart
rate and BMI. Changes in variables over time during the
infusion of Intralipid® and heparin were assessed using the
General Linear Model for repeated measures. Correlations
were determined by Pearson’s method. Statistical analyses
were performed with the SPSS/PC 20.0 statistical software
package (SPSS, Chicago, IL). A p-value <0.05 was accepted
as statistically significant. All multiple comparisons proce-
dures were taken into consideration after False Discovery
Rate (FDR) as described by Benjamini and Hochberg [18].
Results and discussion
Demographic data for control and metabolic syndrome
groups are shown in Table 1. Values for leptin, adiponectin,
Table 1 Demographic and biochemistry data from






Age (years) 35 38 NS
28-46 26-47
Gender (f/m) 6/6 6/6 NS
Race 7 AA, 5 C 6 AA, 6 C NS
Systolic BP (mm Hg) 132 111 <0.0001
(130-144) (100-126)
Diastolic BP (mm Hg) 91 74 <0.0001
(86-94) (64-82)
Heart Rate (bpm) 77 71 <0.005
(72-84) (60-80)
BMI (kg/m2) 34.1 ± 1.9 22.7 ± 0.5 <0.0001
Waist Circumference (cm) 106 ± 4 78 ± 3 <0.0001
Total-cholesterol (mg/dL) 229 ± 6 173 ± 7 <0.0001
HDL-cholesterol (mg/dL) 47 ± 3 61 ± 5 <0.05
LDL-cholesterol (mg/dL) 152 ± 5 95 ± 6 <0.0001
VLDL-cholesterol (mg/dL) 29 ± 4 16 ± 1 <0.01
Triglycerides (mg/dL) 171 ± 30 81 ± 6 0.01
Glucose (mg/dL) 90 ± 3 83 ± 3 0.08
Insulin (UI/L) 12.5 ± 1. 6.5 ± 0.9 0.01
Sodium (mmol/L) 139.3 ± 0.7 142.0 ± 0.7 0.01
Potassium (mmol/L) 4.34 ± 0.15 4.32 ± 0.08 NS
Data presented as median, minimum, maximum and mean ± SEM.
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and heparin infusion in MetS and control groups are
shown in (Figure 1). As shown, baseline leptin and
ASP/C3adesARG was higher and adiponectin lower in
the MetS than the control group (Figure 1). Plasma
leptin and adiponectin did not change during Intralipid
and heparin infusion in both groups. However, plasma
ASP/C3adesARG increased significantly in the control
group after 2-hours of Intralipid® and heparin infusion.
The control group also showed a positive correlation be-
tween the changes in ASP/C3adesARG and triglycerides
after 2-hours of Intralipid® and heparin infusion (r = 0.80,
p = 0.002). The MetS group showed a negative correlation
between the changes for triglycerides and insulin during
the Intralipid® and heparin infusion (r = 0.80, p = 0.002;
r = -0.65, p = 0.02 for 2 and 4-hours respectively).
The correlations in all subjects combined between
plasma leptin and body mass index (r = 0.77, p = 0.001),
systolic BP (r = 0.73, p = 0.001), and diastolic BP (r = 57,
p = 0.030) were significant. The correlation between leptin
and waist circumference, and heart rate did not achieve
significance after FDR correction. Adiponectin correlated
inversely with waist circumference (r = 0.63, p = 0.008).
Adiponectin correlated negatively with insulin, glucose,HOMAir (r = 0.50-0.63, p < 0.02) and positively with the
total antioxidant capacity (r = 0.50, P < 0.02). We found a
positive correlation between plasma ASP/C3adesARG and
BMI, insulin, HOMAir, and heart rate. After FDR correc-
tion these correlations did not achieve significance.
Plasma NEFAs and triglyderides increased similarly in
MetS and control groups after 4-hours of Intralipid® and
heparin infusion. However, the decrease in triglycerides
1-hour post-infusion was significantly lower in the MetS
group compared to the control group (116 ± 33 versus
282 ± 81 mg/dL, p = 0.01).
In this study, subjects with MetS had higher plasma
leptin, ASP/C3adesARG and lower adiponectin then the
normal subjects (Figure 1).
These three adipocyte-derived factors showed a differ-
ential relationship to various components of MetS as de-
scribed above. The findings are consistent with previous
studies, which suggest that adipocytes play an important
role in the pathogenesis of MetS and its complications.
Collectively, evidence indicates that the level of and bal-
ance between specific adipocyte-derived peptides and lipids
may modulate the expression of the hemodynamic and
metabolic components of the insulin resistance syndrome.
Leptin has been implicated as a key transducing factor
between obesity and hypertension [19]. Leptin’s pressor
effects appear to be mediated in large part by activation of
the sympathetic nervous system. While insulin and leptin
are both elevated with obesity and both activate the ner-
vous system, the actions of leptin appear to predominate
[20,21]. In this study, we found a positive correlation be-
tween plasma leptin and body mass index, systolic BP, and
diastolic BP. These findings are consonant with those of
Leyva, et al, who showed a positive correlation between
leptin and BMI, systolic and diastolic BP [22]. Another
important results in this study are related to the nega-
tive correlation between adiponectin insulin, glucose,
HOMAir and waist circumference. These results suggest a
negative correlation between insulin resistance and adipo-
nectin. Since adiponectin, is an adipocyte-derived collagen-
like protein that has been associated to anti-inflammatory
and anti-atherogenic proprieties, it makes sense that sub-
jects with features of insulin resistance, a cardiovascular
risk factor, are supposed to show lower plasma adiponectin
levels. We also found a positive correlation between adipo-
nectin and the total antioxidant capacity (FRAP assay),
although it disappeared after FDR correction. It suggests
that the highest the total antioxidant capacity better are
the anti-atherogenic and anti-inflammatory profiles.
Maslowska and coworkers showed a higher plasma
ASP/C3adesARG in obese than non-obese subjects and
suggested that ASP/C3adesARG pathway has involvement
in the pathogenesis of obesity [23]. Since subjects with the
features of MetS have a high triglycerides level comparing
to normal subjects and the ASP/C3adesARG is associated
Figure 1 Plasma leptin, adiponectin and ASP/C3adesARG values at baseline and after Intralipid® infusion in control and metabolic
syndrome groups. *p<0.05.
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level of ASP/C3adesARG in obese subjects can be a sign
of a malfunctioning mechanism of this protein. Plasma
ASP/C3adesARG increased significantly in control group
during Intralipid® and heparin infusion. Meijssen et al
showed an increased post-prandial ASP/C3adesARG re-
sponse in subjects with familial combined hyperlipidemia
[24]. Halkes et al. also showed an increase in plasma ASP/
C3adesARG after oral lipid load in normolipemic sub-
jects with coronary artery disease and normal volunteers
[10]. Although this two studies showed an increase in
C3adesARG in humans exposed to an oral lipid load, the
results over the literature is not concordant. For instance,
Charlesworth et al did not find any change to post-
prandial plasma ASP/C3adesARG in healthy subjects
submitted to an oral lipid load [9]. Even though, the au-
thors observed an important individual variation in post-
prandial plasma ASP/C3adesARG levels in their study. In
our study, the changes in plasma ASP/C3adesARG alsocorrelated to changes on triglycerides in control subjects
during Intralipid® and heparin infusion. The postprandial
triglycerides clearance was delayed in MetS comparing to
control group. In experimental study, Murray et al. already
showed delayed post-prandial triglycerides clearance in
ASP-deficient mice comparing to wild type [25]. ASP/
C3adesARG is already known as a complement 3 frag-
ment related to triglycerides clearance [8]. However, this is
the first time that evidence of a blunted release of ASP/
C3adesARG in subjects with the cluster of cardiovascular
risk factors submitted to an Intralipid® and heparin infu-
sion, a model of acute hyperlipidemia, is showed. Since
MetS group, which has higher fasting plasma triglycerides,
did not show any increase in ASP/C3adesARG during
Intralipid® and heparin infusion and also showed lower
triglycerides clearance after an Intralipid® and heparin
infusion, we can speculate a possible deficiency of ASP/
C3adesARG synthesis in MetS subjects exposed to an
acute hyperlipidemia.
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In conclusion, subjects with features of MetS have higher
leptin, ASP/C3adesARG, and lower plasma level of adipo-
nectin. They also showed lower triglycerides clearance and
ASP/C3adesARG responses to an acute hyperlipidemia.
These findings, taken together with previous reports, sug-
gest that these adipocyte-derived factors play an important
role in the pathogenesis and complications of MetS. The
results further suggest that the levels of and balance
between the various adipocyte derived factors may modu-
late the expression of various metabolic and hemodynamic
facets of the syndrome. The differential impact of vari-
ous adipocyte factors on individual components of the
syndrome raises the potential for additional therapeutic
targets.
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